Teva Pharmaceutical Industries (NYSE:TEVA) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a hold rating to a buy rating in a research note released on Wednesday.

A number of other equities research analysts have also issued reports on the company. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Bank of America reduced their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Finally, UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.18 on Wednesday. The company has a 50-day moving average of $17.79 and a 200-day moving average of $18.21. The firm has a market cap of $18.34 billion, a price-to-earnings ratio of -11.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a twelve month low of $12.51 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently made changes to their positions in TEVA. Stifel Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. grew its stake in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after purchasing an additional 33,277 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in Teva Pharmaceutical Industries by 21.8% in the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,218 shares in the last quarter. Sio Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $24,314,000. Finally, Pinnbrook Capital Management LP acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $4,966,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.